ProxyBio
PrivateLast Round
Seed
May 26, 2026
Total Funding Raised
$3.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ProxyBio, Inc. is a biotechnology company that has developed a stem cell-derived 3D culture system designed for research and therapeutic development in complex diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ProxyBio Comparables
Compare ProxyBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vivodyne | 81% | |
| KYAN Technologies | 79% | |
| Signet Therapeutics | 76% | |
ProxyBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 26, 2026 |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 26, 2026
Raised $4M in seed funding.
ProxyBio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ProxyBio's valuation, stock price, and market status.